Loading
A phase 2/3 trial of Futibatinib, Fulvestrant in metastatic cancer, run by Taiho Oncology, Inc., active and no longer recruiting.
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. is a phase 2/3 interventional study registered as NCT06506955 by Taiho Oncology, Inc., with 15 participants planned, started 2024-10-01 and due to reach its primary completion in 2027-04. Interventions recorded: futibatinib, futibatinib, fulvestrant. Conditions listed: Advanced/Metastatic Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
Shares Fulvestrant, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors.
Shares Fulvestrant, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors.
Shares Fulvestrant, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors.
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
Shares Fulvestrant, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/